Out of 2 analysts covering Anthera Pharmaceuticals (NASDAQ:ANTH), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Anthera Pharmaceuticals has been the topic of 4 analyst reports since September 17, 2015 according to StockzIntelligence Inc. H.C. Wainwright initiated the stock on July 8 with “Buy” rating. Below is a list of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) latest ratings and price target changes.
08/07/2016 Broker: H.C. Wainwright Rating: Buy New Target: $10.00 Initiate
About 238,708 shares traded hands. Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has risen 29.67% since February 8, 2016 and is uptrending. It has outperformed by 13.19% the S&P500.
Anthera Pharmaceuticals, Inc. is a biopharmaceutical firm focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The company has a market cap of $138.98 million. The Firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. It currently has negative earnings. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions.
The institutional sentiment increased to 1.7 in 2016 Q2. Its up 0.76, from 0.94 in 2016Q1. The ratio increased, as 6 funds sold all Anthera Pharmaceuticals Inc shares owned while 14 reduced positions. 5 funds bought stakes while 29 increased positions. They now own 22.69 million shares or 1.80% less from 23.11 million shares in 2016Q1.
Sio Capital Management Llc holds 4% of its portfolio in Anthera Pharmaceuticals Inc for 2.54 million shares. Proquest Associates Iv Llc owns 1.90 million shares or 2.39% of their US portfolio. Moreover, Abingworth Llp has 1.41% invested in the company for 437,994 shares. The New York-based Hilltop Park Associates Llc has invested 0.97% in the stock. Broadfin Capital Llc, a New York-based fund reported 1.15 million shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.